Sunday, July 07, 2019 3:30:36 PM
Docnj,
You made a terrific case that examines the reasons why physicians can be slow to adapt to new treatment options. But I'm the wrong guy who would find his way to empathize with the status quo. You see, my dad was a talented Internist-Hemo/Onc who authored an early study which explained the MO of a common drug we use today. My brother, who teaches and practices in the same area of medicine as dad did, was the first to write Vascepa in the States. Had it not been for him, I wouldn't have asked for a script, as I've taken Vascepa since 2013 for prevention, not out of necessity. Perhaps I'm spoiled to have such influences in the medical field. Bro is someone who gets up in the morning wanting to be that clinician who figured out how to treat a patient, who otherwise, faced the certainty of having inferior results for having gone to someone else. I've never met anyone with such a ferocious appetite to learn and to stay ahead of his or her field.
Bro and I took Mom to a Cardiologist whose at the top of his field out of Colombia Presbyterian. The Cardiologist was Deepak Bhaat's Professor at Cornell. During the middle of the examination, the Doctor says to me, "Your brother is really ahead of his time". "He is the only Doctor in the area who practices prevention as he does"
Let's assume I'm a high-risk CVD patient, the idea that I would consider playing Russian Roulette with my life by choosing to see a "Good doctor", rather than going to the "best Doctor" is imbecilic in my estimation. This isn't interior decorating. You're a physician man, lives in your hands. If you're not going to practice medicine at such a high level, find something else to do.
JMO,
ILT
You made a terrific case that examines the reasons why physicians can be slow to adapt to new treatment options. But I'm the wrong guy who would find his way to empathize with the status quo. You see, my dad was a talented Internist-Hemo/Onc who authored an early study which explained the MO of a common drug we use today. My brother, who teaches and practices in the same area of medicine as dad did, was the first to write Vascepa in the States. Had it not been for him, I wouldn't have asked for a script, as I've taken Vascepa since 2013 for prevention, not out of necessity. Perhaps I'm spoiled to have such influences in the medical field. Bro is someone who gets up in the morning wanting to be that clinician who figured out how to treat a patient, who otherwise, faced the certainty of having inferior results for having gone to someone else. I've never met anyone with such a ferocious appetite to learn and to stay ahead of his or her field.
Bro and I took Mom to a Cardiologist whose at the top of his field out of Colombia Presbyterian. The Cardiologist was Deepak Bhaat's Professor at Cornell. During the middle of the examination, the Doctor says to me, "Your brother is really ahead of his time". "He is the only Doctor in the area who practices prevention as he does"
Let's assume I'm a high-risk CVD patient, the idea that I would consider playing Russian Roulette with my life by choosing to see a "Good doctor", rather than going to the "best Doctor" is imbecilic in my estimation. This isn't interior decorating. You're a physician man, lives in your hands. If you're not going to practice medicine at such a high level, find something else to do.
JMO,
ILT
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
